Yahoo Finance

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
Yahoo Finance

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of ...
Nature

Cer(d18:1/16:0) as a biomarkers for acute coronary syndrome in Chinese populations

Ceramides play a crucial role in atherosclerosis progression and have been linked to cardiovascular events. The objective of this study was to investigate the association between serum ceramide levels ...
Nasdaq

CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation

Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
PharmaTimes

CERo reports encouraging early data from phase 1 trial of CER‑1236

CER‑T therapy shows initial safety signals and prompts protocol expansion CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...